[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 23, 1988

Lack of Response to Recombinant Hepatitis B Vaccine in Nonresponders to the Plasma Vaccine

Author Affiliations

From the Liver Center, Huntington Memorial Hospital, Pasadena, Calif (Drs Weissman, Tsuchiyose, Tong, and Chin and Ms Co), and the Division of Pediatric Nephrology, University of California, Los Angeles Medical Center (Dr Ettenger).

From the Liver Center, Huntington Memorial Hospital, Pasadena, Calif (Drs Weissman, Tsuchiyose, Tong, and Chin and Ms Co), and the Division of Pediatric Nephrology, University of California, Los Angeles Medical Center (Dr Ettenger).

JAMA. 1988;260(12):1734-1738. doi:10.1001/jama.1988.03410120080031
Abstract

Yeast recombinant hepatitis B vaccine was administered to 25 nonresponders to the plasma-derived hepatitis B vaccine. After three 10-μg doses, nine subjects (36%) produced levels of antibodies to hepatitis B surface antigen (antiHBs) of less than 2.1 sample ratio units (SRU) (nonresponders), and five (20%) developed anti-HBs of 2.1 to 9.9 SRU (hyporesponders); anti-HBs levels of 10 SRU or greater were detected at least once in 11 vaccinees (44%), but by the sixth and 12th months after the last vaccination, only three and one of these "responders," respectively, still maintained anti-HBs values of 10 SRU or greater. In these 25 subjects HLA subtyping showed a high prevalence of DR7, B8, and the combinations of DR3 and DR7 and DR4 and DR7. Our findings indicate that the yeast recombinant hepatitis B vaccine was not effective in eliciting a sustained anti-HBs response in nonresponders to the plasma hepatitis B vaccine.

(JAMA 1988;260:1734-1738)

×